GlassScriptPhysician profile
William J Estrin
NPI 1952482390
$3,865.93
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,126 · 2020: $355 · 2021: $768 · 2022: $241 · 2023: $246 · 2024: $129.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $375.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $375.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $468.71 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $387.28 | 2019 | |
| Neurocrine Biosciences, INC. | $380.55 | 2019-2022 | |
| Adamas Pharmaceuticals, INC. | $255.78 | 2019-2020 | |
| Amgen INC. | $232.44 | 2020-2021 | |
| Gilead Sciences, INC. | $230.95 | 2019-2023 | Vemlidy |
| Novartis Pharmaceuticals Corporation | $212.24 | 2019 | |
| Janssen Pharmaceuticals, INC | $200.87 | 2019-2024 | Xarelto |
| Biogen, INC. | $182.75 | 2019-2021 | |
| Mallinckrodt Enterprises LLC | $144.90 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $125.00 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $124.99 | 2023 | Jardiance |
| Astellas Pharma US INC | $124.71 | 2019 | |
| Alexion Pharmaceuticals, INC. | $120.24 | 2019 | |
| Coherus Oncology, INC. | $120.03 | 2020 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dynavax Technologies Corporation | $117.16 | 2019 | |
| Puma Biotechnology, INC. | $115.46 | 2019 | |
| Avanir Pharmaceuticals, INC. | $115.32 | 2019 | |
| Glaxosmithkline, LLC. | $109.23 | 2019 | |
| Exelixis INC. | $97.32 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Estrin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.